DOCSLIB.ORG

Bile Acid Diarrhoea 2019 Jan 4Th Version 6.0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bile Acid Diarrhoea 2019 Jan 4Th Version 6.0 SINBAD: Sequestrant in Bile Acid Diarrhoea 2019 Jan 4th version 6.0 SINBAD Treatment effect of colesevelam for bile acid diarrhoea – a randomised placebo-controlled trial. Danish Region Zealand scientific ethics committee: SJ-641 EudraCT number: 2016-001452-22 SJ-641 EudraCT number: 2016-001452-22 Page 1 of 30 SINBAD: Sequestrant in Bile Acid Diarrhoea 2019 Jan 4th version 6.0 TABLE of CONTENTS Primary research group.................................................................. Fejl! Bogmærke er ikke defineret. Study locations ..................................................................................................................................... 4 Monitoring ........................................................................................................................................... 5 Abbreviations ....................................................................................................................................... 5 Aim ....................................................................................................................................................... 6 Summary of expected improvements from the study ........................................................................ 6 Background .......................................................................................................................................... 6 Bile acid diarrhoea ....................................................................................................................... 6 Present diagnosis of bile acid diarrhoea ...................................................................................... 7 Biochemical markers of bile acid diarrhoea ................................................................................ 7 Biochemical tests in our population – choice of C4 cutoff .......................................................... 8 Treatment of Bile Acid Diarrhoea ................................................................................................ 9 Design ................................................................................................................................................. 10 Study subjects ............................................................................................................................ 10 Inclusion criteria ......................................................................................................................... 10 Exclusion criteria ........................................................................................................................ 10 Endpoints ........................................................................................................................................... 11 Primary endpoint ....................................................................................................................... 11 Secondary endpoints ................................................................................................................. 11 Descriptive endpoints and ancillary analytic endpoints ............................................................ 12 Ancillary endpoints for Patient Reported Outcomes ................................................................. 12 Power calculation ............................................................................................................................... 13 Methods ............................................................................................................................................. 13 Bristol stool form scale .............................................................................................................. 13 Response criteria in chronic watery diarrhoea – Hjortswangs criteria ..................................... 13 Patient reported outcomes ........................................................................................................ 14 Blinding............................................................................................................................................... 15 Emergency unblinding ............................................................................................................... 15 Randomisation ................................................................................................................................... 16 Biochemistry ...................................................................................................................................... 16 Biobank .............................................................................................................................................. 16 Study medication ............................................................................................................................... 16 Colesevelam ............................................................................................................................... 16 SJ-641 EudraCT number: 2016-001452-22 Page 2 of 30 SINBAD: Sequestrant in Bile Acid Diarrhoea 2019 Jan 4th version 6.0 Placebo ....................................................................................................................................... 18 Study plan........................................................................................................................................... 19 Pre-screening – Written invitation............................................................................................. 19 Study visit 1 – Inclusion and start of baseline registration ........................................................ 19 Study visit 2 – Assessment of eligibility by stool diary results ................................................... 21 Telephone consultation: Start of intervention .......................................................................... 22 Telephone consultation: Start of endpoint period – compliance and AEs ................................ 23 Study visit 3 – Treatment end and repeated questionnaires (Q-int) ......................................... 23 End of the clinical study phase................................................................................................... 23 Six-month follow-up ................................................................................................................... 24 Adverse events ................................................................................................................................... 24 Schedule ............................................................................................................................................. 24 Rights .................................................................................................................................................. 24 Planned publications .......................................................................................................................... 25 Ethics .................................................................................................................................................. 25 Recruiting ........................................................................................................................................... 25 Information and consent ........................................................................................................... 25 Results ........................................................................................................................................ 26 Risks and nuisances .................................................................................................................... 26 Data security and access .................................................................................................................... 26 Data from the participants’ medical chart ................................................................................. 27 Primary data responsibility .................................................... Fejl! Bogmærke er ikke defineret. Investigators with data access for analysis ............................ Fejl! Bogmærke er ikke defineret. Economy ............................................................................................................................................. 27 Compensation and insurance in case of injury caused by the study ......................................... 27 References.......................................................................................................................................... 27 Appendix 1: Study overview chart ..................................................................................................... 30 SJ-641 EudraCT number: 2016-001452-22 Page 3 of 30 SINBAD: Sequestrant in Bile Acid Diarrhoea 2019 Jan 4th version 6.0 Study locations Zealand University Hospital Department of Internal Medicine, Section of Gastroenterology Lykkebækvej 1, DK-4600 Køge Hvidovre University Hospital: Gastro-Unit, Medical Division DK-2650 Hvidovre, Kettegårds Allé 30, DK-2650 Hvidovre Department of Clinical Physiology and Nuclear Medicine DK-2650 Hvidovre, Kettegårds Allé 30, DK-2650 Hvidovre Aarhus University Hospital: Hepato-gastroenterological Department V Skejby Hospital, Palle Juul-Jensens Blvd., 8200 Aarhus N Department of Nuclear Medicine and PET Skejby Hospital, Palle Juul-Jensens Blvd., 8200 Aarhus N Aalborg University Hospital: Department of Medical Gastroenterology Aalborg
Load more

Recommended publications
  • Does Your Patient Have Bile Acid Malabsorption?
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 Carol Rees Parrish, MS, RDN, Series Editor Does Your Patient Have Bile Acid Malabsorption? John K. DiBaise Bile acid malabsorption is a common but underrecognized cause of chronic watery diarrhea, resulting in an incorrect diagnosis in many patients and interfering and delaying proper treatment. In this review, the synthesis, enterohepatic circulation, and function of bile acids are briefly reviewed followed by a discussion of bile acid malabsorption. Diagnostic and treatment options are also provided. INTRODUCTION n 1967, diarrhea caused by bile acids was We will first describe bile acid synthesis and first recognized and described as cholerhetic enterohepatic circulation, followed by a discussion (‘promoting bile secretion by the liver’) of disorders causing bile acid malabsorption I 1 enteropathy. Despite more than 50 years since (BAM) including their diagnosis and treatment. the initial report, bile acid diarrhea remains an underrecognized and underappreciated cause of Bile Acid Synthesis chronic diarrhea. One report found that only 6% Bile acids are produced in the liver as end products of of British gastroenterologists investigate for bile cholesterol metabolism. Bile acid synthesis occurs acid malabsorption (BAM) as part of the first-line by two pathways: the classical (neutral) pathway testing in patients with chronic diarrhea, while 61% via microsomal cholesterol 7α-hydroxylase consider the diagnosis only in selected patients (CYP7A1), or the alternative (acidic) pathway via or not at all.2 As a consequence, many patients mitochondrial sterol 27-hydroxylase (CYP27A1). are diagnosed with other causes of diarrhea or The classical pathway, which is responsible for are considered to have irritable bowel syndrome 90-95% of bile acid synthesis in humans, begins (IBS) or functional diarrhea by exclusion, thereby with 7α-hydroxylation of cholesterol catalyzed interfering with and delaying proper treatment.
    [Show full text]
  • Exponential Increase in Stool Crosslinking Is Mirrored in Systemic Inflammation and Associated to Fecal Acetate and Methionine
    H OH metabolites OH Article The Importance of Objective Stool Classification in Fecal 1H-NMR Metabolomics: Exponential Increase in Stool Crosslinking Is Mirrored in Systemic Inflammation and Associated to Fecal Acetate and Methionine Leon Deutsch 1 and Blaz Stres 1,2,3,4,* 1 Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, SI-1000 Ljubljana, Slovenia; [email protected] 2 Faculty of Civil and Geodetic Engineering, University of Ljubljana, Jamova 2, SI-1000 Ljubljana, Slovenia 3 Department of Automation, Jožef Stefan Institute, Biocybernetics and Robotics, Jamova 39, SI-1000 Ljubljana, Slovenia 4 Department of Microbiology, University of Innsbruck, Technikerstrasse 25d, A-6020 Innsbruck, Austria * Correspondence: [email protected]; Tel.: +386-41-567-633 Abstract: Past studies strongly connected stool consistency—as measured by Bristol Stool Scale (BSS)—with microbial gene richness and intestinal inflammation, colonic transit time and metabolome characteristics that are of clinical relevance in numerous gastro intestinal conditions. While retention time, defecation rate, BSS but not water activity have been shown to account for BSS-associated Citation: Deutsch, L.; Stres, B. The inflammatory effects, the potential correlation with the strength of a gel in the context of intestinal Importance of Objective Stool forces, abrasion, mucus imprinting, fecal pore clogging remains unexplored as a shaping factor for Classification in Fecal 1H-NMR intestinal inflammation and has yet to be determined. Our study introduced a minimal pressure ap- Metabolomics: Exponential Increase proach (MP) by probe indentation as measure of stool material crosslinking in fecal samples. Results in Stool Crosslinking Is Mirrored in reported here were obtained from 170 samples collected in two independent projects, including males Systemic Inflammation and and females, covering a wide span of moisture contents and BSS.
    [Show full text]
  • A Deep Learning Approach to Human Stool Recognition And
    Augmenting Gastrointestinal Health: A Deep Learning Approach to Human Stool Recognition and Characterization in Macroscopic Images David Hachuel Akshay Jha Deborah Estrin, PhD Cornell Tech Cornell Tech Cornell Tech Cornell University Cornell University Cornell University New York, NY, USA New York, NY, USA New York, NY, USA [email protected] [email protected] [email protected] Alfonso Martinez Kyle Staller, MD, MPH Christopher Velez, MD Massachusetts Institute Massachusetts General Massachusetts General of Technology Hospital Hospital Cambridge, MA, USA Boston, MA, USA Boston, MA, USA [email protected] [email protected] [email protected] ABSTRACT Results - In terms of inter-rater reliability, the Kappa score UPDATED—4 December 2018. Purpose - Functional ​ was κ = 0.5840. Regarding the stool detection task, our bowel diseases, including irritable bowel syndrome, chronic modified SegNet produced a 71.93% mIoU on a test set of constipation, and chronic diarrhea, are some of the most 282 images when trained on 651 images. Current common diseases seen in clinical practice. Many patients state-of-the-art segmentation models reach 83.2% mIoU describe a range of triggers for altered bowel consistency when trained on significantly larger datasets. As for BSS and symptoms. However, characterization of the classification using the ResNet architecture, our mean relationship between symptom triggers using bowel diaries accuracy is 74.26% on a test set of 272 images when trained is hampered by poor compliance and lack of objective stool on 614 images. In comparison, the ResNet trained on the consistency measurements. We sought to develop a stool secondary dataset achieved 99.4% accuracy in classifying detection and tracking system using computer vision and BSS on a test set of 10800 images when trained on 25200 deep convolutional neural networks (CNN) that could be images.
    [Show full text]
  • And Sulphate-Rich Natural Mineral Water in Functional Constipation
    Nutrition 65 (2019) 167À172 Contents lists available at ScienceDirect Nutrition journal homepage: www.nutritionjrnl.com Applied nutritional investigation Time to treatment response of a magnesium- and sulphate-rich natural mineral water in functional constipation Christophe Dupont M.D., Ph.D. a,*, Florence Constant M.D., Ph.D. b, Aurelie Imbert M.Sc. b, Guillaume Hebert Ph.D., M.B.A. c, Othar Zourabichvili M.D., Ph.D. d, Nathalie Kapel Pharm.D., Ph.D. e a Service d'Explorations Fonctionnelles Digestives Pediatriques, AP-HP, Hopital^ Necker Enfant Malade, Universite Paris Descartes, Paris, France b Nestle Waters M.T., Issy-les-Moulineaux, France c SC Partners, Paris, France d Quanta Medical, Rueil-Malmaison, France e Laboratoire de Coprologie Fonctionnelle, Hopitaux^ Universitaires Pitie Salp^etriere - Charles Foix, APHP, Paris, France ARTICLE INFO ABSTRACT Article History: Objectives: First-line recommendations for the management of functional constipation include nutritional- Received 11 June 2018 hygienic measures. We previously showed that a natural mineral water rich in sulphates and magnesium Received in revised form 22 February 2019 (Hepar) is efficient in the treatment of functional constipation. The aim of this study was to consolidate those Accepted 24 February 2019 first results and determine a precise time to respond to Hepar. Keywords: Methods: This multicenter, randomized, double-blind, controlled study of the effect of Hepar on stool consis- Bowel movement tency and frequency in functional constipation included 226 outpatients. After washout, patients used 1.5 L Functional constipation of water daily, including 1 L of Hepar or of low-mineral water, during 14 d. In addition to a daily reporting of Clinical trial stool consistency by the patient, an expert investigator blindly analyzed stool consistency (Bristol stool scale) Natural mineral water based on photographs taken by the patient.
    [Show full text]
  • Bowel Health
    Bowel Health • Prevention of Constipation • and Bowel obstruction Definition • Constipation is infrequent bowel movements or difficult passage of stools. Constipation is a common gastrointestinal problem. • What's considered normal frequency for bowel movements varies widely. In general, however, you're probably experiencing constipation if you pass fewer than three stools a week, and your stools are hard and dry. Prevention • Fortunately, most cases of constipation are temporary. Simple lifestyle changes, such as getting more exercise, drinking more fluids and eating a high-fiber diet, can go a long way toward alleviating constipation. Constipation may also be treated with stool softeners or over-the-counter laxatives. Symptoms • Pass fewer than three stools a week • Experience hard stools • Strain excessively during bowel movements • Experience a sense of rectal blockage • Have a feeling of incomplete evacuation after having a bowel movement Documentaion- Providers must maintain documentation concerning the amount and type if the individual has chronic constipation or takes medication to assist with evacuation. Many home providers use a BM Log. It is important to have a written plan by the doctor to include: Type of diet, fluid recommendations or restrictions, type of sttol softeners or laxatives and when to call the doctor for further instructions. Some doctors prescribe a laxative, enema or suppository if no stool for 3 days. • The Bristol Stool Form Scale The Bristol Stool Scale or Bristol Stool Chart is a medical aid designed to classify the form of human feces into seven groups. It was developed by Heaton and Lewis at the University of Bristol and was first published in the Scandinavian Journal of Gastroenterology in 1997.
    [Show full text]
  • Bile Acid Diarrhoea: Pathophysiology, Diagnosis and Management
    SMALL BOWEL AND NUTRITION Frontline Gastroenterol: first published as 10.1136/flgastro-2020-101436 on 22 September 2020. Downloaded from REVIEW Bile acid diarrhoea: pathophysiology, diagnosis and management Alexia Farrugia ,1,2 Ramesh Arasaradnam 2,3 1Surgery, University Hospitals ABSTRACT Coventry and Warwickshire NHS Key points The actual incidence of bile acid diarrhoea Trust, Coventry, UK 2Divison of Biomedical Sciences, (BAD) is unknown, however, there is increasing ► Idiopathic bile acid diarrhoea (BAD) is due University of Warwick, Warwick evidence that it is misdiagnosed in up to 30% Medical School, Coventry, UK to overproduction of bile acids (rather with diarrhoea-pr edominant patients with 3Gastroenterology, University than malabsorption). Hospitals of Coventry and irritable bowel syndrome. Besides this, it may ► The negative feedback loops involved in Warwickshire NHS Trust, also occur following cholecystectomy, infectious bile acid synthesis are interrupted in BAD Coventry, UK diarrhoea and pelvic chemoradiotherapy. but there is lack of data regarding what BAD may result from either hepatic Correspondence to causes the interruption. Professor Ramesh Arasaradnam, overproduction of bile acids or their ► There is increasing evidence of an Gastroenterology, University malabsorption in the terminal ileum. It can result interplay between the gut microbiota, Hospitals of Coventry and in symptoms such as bowel frequency, urgency, farnesoid X receptor and fibroblast growth Warwickshire NHS Trust, factor 19 in BAD. Coventry CV2 2DX, UK; R. nocturnal defecation, excessive flatulence, Tests for BAD such as SeHCAT are not Arasaradnam@ warwick. ac. uk abdominal pain and incontinence of stool. ► available worldwide but alternatives Bile acid synthesis is regulated by negative Received 18 February 2020 include plasma C4 testing and possibly Revised 14 May 2020 feedback loops related to the enterohepatic faecal bile acid measurement.
    [Show full text]
  • Food, Fibre, Bile Acids and the Pelvic Floor: an Integrated Low Risk Low Cost Approach to Managing Irritable Bowel Syndrome
    Submit a Manuscript: http://www.wjgnet.com/esps/ World J Gastroenterol 2015 October 28; 21(40): 11379-11386 Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx ISSN 1007-9327 (print) ISSN 2219-2840 (online) DOI: 10.3748/wjg.v21.i40.11379 © 2015 Baishideng Publishing Group Inc. All rights reserved. TOPIC HIGHLIGHT 2015 Advances in irritable bowel syndrome Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R syndrome, and medications may be used often without Gibson, Monash University, Eastern Health, The Alfred Hospital, success. Advances in the understanding of the causes Melbourne 3128, Australia of the symptoms (including pelvic floor weakness and incontinence, bile salt malabsorption and food Author contributions: Philpott H proposed, conceptualised, intolerance) mean that effective, safe and well tolerated researched and wrote the paper; Nandurkar S researched and treatments are now available. suggested modifications; Lubel J edited the paper; Gibson PR provided previous literature and concepts related to dietary treatment. Key words: Bile acids; Pelvic floor; Food intolerance; Irritable bowel syndrome; Diarrhoea Conflict-of-interest statement: The authors have no conflict of interest to report. © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external Core tip: Decreasing the dietary intake of poorly reviewers. It is distributed in accordance with the Creative absorbed carbohydrates and/or using bile acid binders Commons Attribution Non Commercial (CC BY-NC 4.0) license, can greatly decrease symptoms of diarrhoea.
    [Show full text]
  • JNM J Neurogastroenterol Motil, Vol. 25 No. 4 October, 2019
    J Neurogastroenterol Motil, Vol. 25 No. 4 October, 2019 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm17134 JNM Journal of Neurogastroenterology and Motility Original Article Prevalence and Severity of Fecal Incontinence in Veterans Amy E Hosmer,1 Sameer D Saini,2,3,4 and Stacy B Menees2,3* 1Division of Gastroenterology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA; 2Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; 3Division of Gastroenterology, Department of Internal Medicine, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI, USA; and 4VA HSR&D Center for Clinical Management Research, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI, USA Background/Aims Fecal incontinence (FI) is a common complaint that increases in prevalence with age. Our aim was to determine the prevalence of FI and assess its severity by self-report in a male-predominant Veteran outpatient clinic setting. Methods An anonymous 28 item questionnaire was administered to a convenience sample of veterans awaiting appointments. FI was defined as a loss of liquid or solid stool at least monthly. Multivariable logistic and linear models were used to identify predictors of FI prevalence and severity. Results One hundred thirty-three gastroenterology (GI) participants and 126 primary care (PC) participants completed the survey. Ninety-four of 259 participants (36.3%, 95% confidence interval [CI]: 30.4-42.5) reported an episode of FI (41.4% GI participants vs 31.0% PC participants; P = 0.078) with 33.6% having FI within the last 30 days (36.8% GI participants vs 30.2% PC participants; P = 0.122).
    [Show full text]
  • Inborn Errors of Bile Acid Metabolism
    Reprinted with permission from Thieme Medical Publishers (Seminars Liver Dis. 2007 Aug;27(3):282-294) Homepage at www.thieme.com Inborn Errors of Bile Acid Metabolism James E. Heubi, M.D.,1 Kenneth D.R. Setchell, Ph.D.,1 and Kevin E. Bove, M.D.1 ABSTRACT Bile acids are synthesized by the liver from cholesterol through a complex series of reactions involving at least 14 enzymatic steps. A failure to perform any of these reactions will block bile acid production with failure to produce ‘‘normal bile acids’’ and, instead, result in the accumulation of unusual bile acids and intermediary metabolites. Failure to synthesize bile acids leads to reduced bile flow and decreased intraluminal solubilization of fat and fat-soluble vitamins. In some circumstances, the intermediates created because of blockade in the bile acid biosynthetic pathway may be toxic to hepatocytes. Nine recognized inborn errors of bile acid metabolism have been identified that lead to enzyme deficiencies and impaired bile acid synthesis in infants, children, and adults. Patients may present with neonatal cholestasis, neurologic disease, or fat and fat-soluble vitamin malabsorption. If untreated, progressive liver disease may develop or reduced intestinal bile acid concentrations may lead to serious morbidity or mortality. This review focuses on a description of the disorders of bile acid synthesis that are directly related to single defects in the metabolic pathway, their proposed pathogenesis, treatment, and prognosis. KEYWORDS: Cholestasis, bile acid, cholic acid, liver Bile
    [Show full text]
  • Irritable Bowel Syndrome
    Otterbein University Digital Commons @ Otterbein Nursing Student Class Projects (Formerly MSN) Student Research & Creative Work Summer 2020 Irritable Bowel Syndrome Katherine Stillman Otterbein University, [email protected] Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn Part of the Nursing Commons Recommended Citation Stillman, Katherine, "Irritable Bowel Syndrome" (2020). Nursing Student Class Projects (Formerly MSN). 416. https://digitalcommons.otterbein.edu/stu_msn/416 This Project is brought to you for free and open access by the Student Research & Creative Work at Digital Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an authorized administrator of Digital Commons @ Otterbein. For more information, please contact [email protected]. Irritable Bowel Syndrome Katherine J. Stillman, BSN, RN Otterbein University, Westerville, Ohio Introduction Gut Microbiome Pathophysiology Visceral Hypersensitivity Genetics Irritable bowel syndrome (IBS) has been defined as a poorly understood, chronic Normal gut microbiota within the human . Visceral hypersensitivity in IBS is the . Concordance for IBS is greater among monozygotic twins. gastrointestinal (GI) disorder without clear physical or biochemical dysfunction, intestine is complex, involving thousands of IBS is a complex disorder and is perception of pain in the bowel in response Having a parent with IBS tends to be a greater predictor of relating symptoms to psychological causes. Recent evidence proposes new microbial species working together to maintain unlikely to be narrowed to down to to normal GI movement. Abnormalities in disease, but social learning may be a factor (Hellström, 2019). understanding of the interaction between the gut and brain, with a focus on the gut homeostasis and protect against pathogens.
    [Show full text]
  • Standard of Care: Anorectal Disorders ICD 10 Codes
    Department of Rehabilitation Services Physical Therapy Standard of Care: Anorectal Disorders ICD 10 Codes: Constipation (outlet dysfunction): K5902 Anal Spasm: K594 Constipation (NEC): K5900 Other Specified Diseases of Anus or Rectum: K6289 Fecal Incontinence (full): R159 Fecal Incontinence (incomplete emptying): R150 Fecal Incontinence (smearing): R151 Fecal Incontinence (fecal urgency): R152 Additional ICD-10 codes that may be used to address common coexisting impairments: Pelvic muscle wasting: N8184 Rectocele: N816 Muscle spasm: M62838 Case Type / Diagnosis: dyssynergic defecation (outlet dysfunction); slow transit constipation, fecal incontinence, anorectal pain/Levator Ani Syndrome, proctalgia fugax Anorectal disorders encompass multiple diagnoses including: dyssynergic defecation, fecal incontinence and levator ani syndrome, all of which are evaluated and treated in pelvic health physical therapy. The current Rome IV diagnostic criterion (released in May 2016), which is the standard for clinical practice and research for functional gastrointestinal disorders, recognizes several anorectal disorders, including: fecal incontinence, functional anorectal pain, and functional defecation disorders and functional constipation.1 Please refer to the tables below for complete review of the Rome IV diagnostic criteria for each condition. 1,2 . Anorectal disorders are common and affect up to 25% of the adult and pediatric population, causing a significant negative impact on quality of life and a burden to health care. 3 The exact definition of fecal incontinence and anal incontinence is important in differential diagnosis for the pelvic floor physical therapist. Fecal incontinence, (FI) as defined by Bharucha, is uncontrolled passage of fecal material recurring for less than or equal to 3 months and is not considered a medical problem before age four.
    [Show full text]
  • Managing Constipation in Older People
    OLDER PERSON’S HEALTH MEDICINES MANAGEMENT GASTROENTEROLOGY Managing constipation in older people Constipation is common in older people due to factors such as multimorbidity, polypharmacy, frailty, dehydration, a lack of exercise and poor diet. Consider dietary, lifestyle and reversible causes first, although pharmacological interventions will be required in many cases. Ideally, the use of laxatives will be temporary, and treatment slowly withdrawn when symptoms resolve, however, long-term use may be necessary in patients with unmodifiable secondary causes of constipation. KEY MESSAGES: Constipation: causes and consequences The possibility of a serious underlying condition, e.g. bowel Constipation may be described as defaecation that is cancer, should be considered in all older patients who report unsatisfactory due to infrequent stools, difficulty passing stools a recent change in bowel habit in combination with other 1 red flag symptoms or signs or a sensation of incomplete evacuation. Patients presenting The goal of constipation management is resolution of with constipation may report hard stools, straining and pain symptoms and a soft, fully-formed stool passed without on defaecation, faecal soiling, abdominal discomfort, nausea, straining at least three times per week, i.e. the lower limit of a bloating, loss of appetite or the need to manually remove healthy frequency of defaecation stools.2, 3 Constipation may be primary, where the cause is Conservative interventions are first-line including advice colonic or anorectal dysfunction, or secondary, when lifestyle, about toileting routine, exercise and diet (ensuring adequate fibre and fluid intake) medicines and/or underlying conditions are the principal cause 4 Optimising management of co-morbidities and the use of (Table 1).
    [Show full text]